Dermira Says Patient Enrollment Closes in Two Phase-3 Trials for Potential Acne Treatment

October 10, 2017

Dermira (DERM), a company involved with dealing with chronic skin conditions, said Thursday patient enrollment in its Clareos 1 and 2 phase 3 clinical trials has been completed. Shares declined more than 1% intraday.

The trials evaluate the efficacy and safety of olumacostat glasaretil – formerly DRM01 – in patients aged nine years and older with facial acne vulgaris, according to a statement. Olumacostat glasaretil is a small molecule designed to target sebum production following topical application.

“We continue to believe that olumacostat glasaretil represents a potential new treatment option for acne with an exciting new mechanism of action that is designed to target sebum,” said Luis Peña, chief development officer at Dermira. “We look forward to sharing topline results from the phase 3 clinical program in the first quarter of next year.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Stephen Holmes

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: